



August 25, 2014

Pharmacy Announcement

## Drug Use Review (DUR) Board Approves Quantity Limits Effective September 9, 2014

The Nevada Medicaid Drug Use Review (DUR) Board met on April 24, 2014, and approved the following quantity limits for Pharmacy point of sale drug claims for utilization management and patient safety.

The following quantity limits are effective September 9, 2014:

**Sovaldi® (sofosbuvir):** 28 caps/rolling 25 days. May be renewed with prior authorization (PA) based on genotype.

**Olysio® (simeprevir):** 28 caps/rolling 25 days.

**Buprenorphine/Naloxone** 2 mg/0.5 mg sublingual tablet/film: 90 tabs/30 days.

**Buprenorphine/Naloxone** 4 mg/1 mg sublingual film: 30 tabs/30 days.

**Buprenorphine/Naloxone** 8 mg/2 mg sublingual tablet/film: 60 tabs/30 days.

**Buprenorphine/Naloxone** 12 mg/3 mg sublingual tablet/film: 30 tabs/30 days.

**Buprenorphine/Naloxone** 1.4 mg/0.36 mg sublingual tablet: 90 tabs/30 days.

**Buprenorphine/Naloxone** 5.7 mg/1.4 mg sublingual tablet: 60 tabs/30 days.

**Buprenorphine** 8 mg sublingual tablet: 60 tabs/30 days.

**Buprenorphine** 2 mg sublingual tablet: 90 tabs/30 days.

**Zohydro® ER (Hydrocodone ER):** 5 tablets per 30 days. No PA criteria to exceed.

**Promethazine VC with Codeine:** 120 ml per fill, up to 3 fills per rolling 12 months. Thirty (30) days of messaging before turning hard stop on. Effective October 9, 2014, claims exceeding 120 ml and/or claims exceeding 3 fills per 365 days will reject.

The following quantity limit is effective September 1, 2014, per a previous DUR Board meeting:

**Effient® (prasugrel):** 30 tablets/30 days.